Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 1,026,117 | 1,011,560 | 1,013,476 | 1,026,623 | 1,059,937 |
| Cost of Goods | 672,404 | 666,717 | 649,391 | 664,783 | 660,960 |
| Gross Profit | 353,713 | 344,843 | 364,085 | 361,840 | 398,977 |
| Operating Expenses | 202,465 | 219,583 | 231,554 | 211,121 | 234,992 |
| Operating Income | 151,652 | 125,977 | 132,922 | 151,502 | 164,945 |
| Interest Expense | 32,769 | 35,001 | 33,544 | 33,742 | 35,044 |
| Other Income | 770 | 8,035 | 109,328 | -4,887 | -1,237 |
| Pre-tax Income | 119,653 | 99,011 | 208,706 | 112,873 | 128,664 |
| Income Tax | 25,392 | 24,529 | 19,754 | 24,852 | 29,221 |
| Net Income Continuous | 94,261 | 74,482 | 188,952 | 88,021 | 99,443 |
| Minority Interests | 180 | 1,522 | 1,868 | 632 | 2,423 |
| Net Income | $94,081 | $72,960 | $187,084 | $87,389 | $97,020 |
| EPS Basic Total Ops | 1.75 | 1.31 | 3.66 | 1.70 | 1.89 |
| EPS Basic Continuous Ops | 1.83 | 1.45 | 3.68 | 1.72 | 1.94 |
| EPS Diluted Total Ops | 1.74 | 1.30 | 3.63 | 1.69 | 1.89 |
| EPS Diluted Continuous Ops | 1.82 | 1.44 | 3.68 | 1.71 | 1.93 |
| EPS Diluted Before Non-Recurring Items | 2.80 | 2.27 | 2.46 | 2.72 | 2.69 |
| EBITDA(a) | $237,734 | $211,334 | $213,436 | $230,372 | $242,616 |